Status:
COMPLETED
The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborating Sponsors:
Patch Rx Technologies
Conditions:
Cystic Fibrosis
Adherence, Medication
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
This proposed pilot study will assess if the Patch Technology system will increase adherence in patients with cystic fibrosis followed at the UTHSCSA Cystic Fibrosis Center.
Detailed Description
This trial will follow patients' adherence with their current medication regimen and will not impact the medications they are prescribed. Patients will be enrolled during a regularly scheduled Cystic ...
Eligibility Criteria
Inclusion
- Diagnosed with CF and cared for at University of Texas Health San Antonio Cystic Fibrosis clinic
- \> 12 years of age
- Prescribed a daily CF specific vitamin for at least 6 month
- Prescribed the genetic modulator elexacaftor/tezacaftor/ivacaftor for at least 6 month
- English speaking
- Patient possesses a Bluetooth enabled smartphone or mobile device.
Exclusion
- 1\) Patient is already using some other medication therapy management (MTM) service.
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 27 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04684823
Start Date
January 15 2021
End Date
December 27 2021
Last Update
January 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229